Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM)

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE220828 | GEO | 2023/12/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [WES]

Project description:Multiple Myeloma (MM) is a neoplasm of plasma cells originating in the bone marrow and is the second most common blood cancer in the United States. One challenge in understanding the pathogenesis of Multiple Myeloma (MM) and improving treatment is a lack of immunocompetent mouse models. We previously developed the IL6Myc mouse that generates plasmacytomas at 100% frequency that phenotypically resemble aggressive MM. Using comprehensive genomic analysis, we found that the RNA expression patterns between tumors were somewhat heterogenous, but nonetheless resembled MMSET (multiple myeloma SET domain), an aggressive form of human myeloma with poor prognosis. Cell lines derived from the mouse tumors expressed cell-surface markers typical of MM, but also expressed BAFF-R, which is infrequently found in human MM. The cell lines also had heterogeneous responses to chemotherapeutic drugs typically used to treat human MM. Interestingly IL6Myc tumors accumulated variants in genes like those seen in human MM, as well as recurrent Ig translocations, a common characteristic of human MM. These data indicate that the IL6Myc model is a useful model for aggressive MM that can be used to develop treatment and understand how early myc expression influences disease etiology.

2023-12-06 | GSE220827 | GEO

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [tumor RNA-seq]

2023-12-06 | GSE220825 | GEO

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [cell line RNA-seq]

2023-12-06 | GSE220823 | GEO

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM)

Project description:The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM)

| PRJNA911669 | ENA

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [WES]

Project description:The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [WES]

| PRJNA911731 | ENA

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [tumor RNA-seq]

Project description:The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [tumor RNA-seq]

| PRJNA911728 | ENA

The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [cell line RNA-seq]

Project description:The IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (MM) [cell line RNA-seq]

| PRJNA911729 | ENA

Multiple myeloma

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-01-24 | GSE125364 | GEO

Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient Registry.

Project description:Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect® MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009-2011; Cohort 2: 2012-2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.

| S-EPMC6899784 | biostudies-literature

The Eµ-myc Mouse Model Represents Heterogeneity Across Human Aggressive B-cell Lymphomas

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-09-10 | E-GEOD-40760 | biostudies-arrayexpress